FoggyIsle.XYZ | Market's view on Ondine Biomed

Destiny’s XF-73 is described as equally effective to OND’s product, immune to resistance issues, and does not require a machine for activation, presenting a competitive challenge to OND.
Destiny’s products potentially target a larger market as they are applicable outside clinical settings.
Concerns are raised about the need for OND to secure financing to stabilize its share price.
Stock Watcher highlights that OND’s Steriwave technology is experiencing significant revenue growth and commercial momentum, with revenues nearly doubling and hospital deployments increasing.
The company is reportedly forming strategic inroads into the NHS in England and has made its first hospital deployment in Australia.
Distribution partnerships are under discussion to potentially accelerate growth and geographical reach.
There is mention of a planned expansion into Intensive Care Units, aiming to replace commonly used antibiotics with Steriwave technology.
There are plans for a US Phase 3 clinical trial in collaboration with HCA Healthcare, which could facilitate FDA approval and adoption in the US.
OND is described as having received funding support indications, which could extend its operational runway.
Stock Watcher comments on the dire need for OND to address its financing to attract potential investors.
There is a concern about how the pricing and adoption of Steriwave depend on individual clinicians’ discretion.
A detailed description of Steriwave’s benefits and its broad-spectrum efficacy, which offers a rapid non-antibiotic approach to decolonizing the nose, reducing hospital-acquired infections, and addressing antimicrobial resistance.